Skip to Main Content

Author Details

James D Brenton
CRUK Cambridge Institute, University of Cambridge
1995
193
64
PMIDPaper TitleJournal TitlePublished Year
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
37752102Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.Nat Commun2023
37845213Molecular landscape and functional characterization of centrosome amplification in ovarian cancer.Nat Commun2023
38057616Deep learning-based segmentation of multisite disease in ovarian cancer.Eur Radiol Exp2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
37348462Positional influence on cellular transcriptional identity revealed through spatially segmented single-cell transcriptomics.Cell Syst2023
37444472Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients.Cancers (Basel)2023
37072323Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.Int J Gynecol Cancer2023
37474499The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.Nat Commun2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36635516Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.Semin Immunopathol2023
36860310Lesion-specific 3D-printed moulds for image-guided tissue multi-sampling of ovarian tumours: A prospective pilot study.Front Oncol2023
34697060DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.Cancer Epidemiol Biomarkers Prev2022
35705807A pan-cancer compendium of chromosomal instability.Nature2022
35398881The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.Clin Cancer Res2022
35694774Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.EMBO Mol Med2022
35785153Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.Front Oncol2022
35690073Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
35714451Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.Eur J Cancer2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
36210504Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.J Natl Cancer Inst2022
36105417Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy.BJR Open2022
36289203Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.Nat Commun2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
33720084Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies.Int J Gynecol Pathol2022
34861371European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.Ann Oncol2022
35121756Refined characterization of circulating tumor DNA through biological feature integration.Sci Rep2022
34897700Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol2022
34789471High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2022
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
33570999FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections.JCO Clin Cancer Inform2021
33782566Promises and challenges of adoptive T-cell therapies for solid tumours.Br J Cancer2021
33752918Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.Gynecol Oncol2021
33607245Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?Semin Cancer Biol2021
34389159Circulating tumour DNA for clinicians: current and future clinical applications.Clin Radiol2021
34561272TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer.Cancer Res2021
33315123Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer.Eur Radiol2021
33398064Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.Br J Cancer2021
32253542Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis.Eur Radiol2020
32075097<i>PIK3R1</i><sup>W624R</sup> Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma.Cells2020
31829441p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.J Pathol2020
33212885Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma.Cancers (Basel)2020
32804260Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer.Insights Imaging2020
32421652Tissue-specific and interpretable sub-segmentation of whole tumour burden on CT images by unsupervised fuzzy clustering.Comput Biol Med2020
32366847Genomic landscape of platinum resistant and sensitive testicular cancers.Nat Commun2020
32249277Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.Br J Cancer2020
32555365Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
  • 1 - 50 of 193

Recommended Authors

Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 4
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 18
Ghassan Allo
Henry Ford Hospital
Career Start Year 2011
Number of shared co-authors 15
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 3
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 7
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 9
Ritu Roy
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 1
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 71
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 5
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 8
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 42
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 24
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 17
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 3
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 9
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 21
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2002
Number of shared co-authors 6
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 3
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 35
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 24
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 7
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 59
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 2
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 13
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 8
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 11
Keith A Baggerly
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 20
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 9
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 131
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 6

Collaborators

Mercedes Jimenez-Linan
University of Cambridge
Co-authored papers 42
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 37
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 37
Anna M Piskorz
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 32
Anna DeFazio
Westmead Hospital
Co-authored papers 30
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 27
David G Huntsman
University of British Columbia
Co-authored papers 27
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 27
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 26
Iain A McNeish
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 25
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 22
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 22
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 22
Martin K??bel
University of Calgary
Co-authored papers 21
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 20
Linda E Kelemen
Hollings Cancer Center, Medical University of South Carolina
Co-authored papers 18
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 18
Jenny Lester
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 18
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 17
Andrew Berchuck
Duke School of Medicine
Co-authored papers 17
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 17
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 17
Jennifer Alsop
University of Cambridge
Co-authored papers 17
Cyril B Gilks
University of British Columbia
Co-authored papers 15
Sian Fereday
Peter MacCallum Cancer Centre
Co-authored papers 15
Stacey J Winham
Mayo Clinic
Co-authored papers 15
Weiva Sieh
Co-authored papers 15
Florian Markowetz
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 15
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 14
Joellen M Schildkraut
Rollins School of Public Health, Emory University
Co-authored papers 14
Release 1.2